- Report ID: BMRC 448 | Number of pages: 197 | Publish Date: Jan 2020
Status: Published | Category: Healthcare | Delivery Timeline:
Anemia Drugs Market report is segmented on the basis of anemia type, end-user and region & country level. Based upon anemia type, global anemia drugs market is segmented into iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia, pernicious anemia and others. Based on end-user, the anemia drugs market is segmented into hospitals, private clinics and other.
Anemia Drugs Market is valued at USD 26292.3 Million in 2018 and expected to reach USD 55279.2 Million by 2025 with the CAGR of 11.20% over the forecast period.
Anemia is a set of conditions characterized by weakness, shortness of breath and a general tiredness due to a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood. Anemia is a common cause of qualitative or quantitative deficiency of hemoglobin. Hemoglobin is iron rich protein that carries the oxygen from lungs to the other parts of body tissue. The hemoglobin deficiency is generally associated with the decrease in the number of red blood cells and hematocrit. Anemia causes low transfer of oxygen to the rest of the body. It is easily preventable and treated however, there are mild or vague symptoms for detection of anemia due to which anemia mostly goes undetectable.
The regions covered in this Global Anemia Drugs Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of anemia drugs is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
Some of the key players in Global Anemia Drugs market are: Amgen Inc., Meda Cuonsumer Healthcare Inc., Johnson and Johnson, Emmaus Medical Inc., Keryx Biopharmaceuticals, Inc., Abbvie Inc, GlaxoSmithKline plc, Pfizer Inc., Allergan Inc., F. Hoffmann La Roche AG, and others.
High Prevalence of Anemia is One of the Major Factors Driving the Growth of Global Anemia Drugs Market.
The increasing rate of nutritional deficiency is one of the major driving factors of anemia drugs market globally. The increase in prevalence of chronic diseases and unhealthy life styles and growing baby bloomer population are some of the factors boosting the growth of anemia drugs market. In addition, increasing government initiatives in improving the healthcare facilities in developing countries is also supplementing the market growth. However, adverse effects associated with the medications of anemia drugs may hamper the market growth. Moreover, increasing research and development associated with the anemia drugs can create new opportunities for the market growth of anemia drugs during the forecast period. Furthermore, the highest number of individuals affected with anemia after pre-school-age children are non-pregnant women which are around 31.2% of the total anemic population. As per WHO, globally anaemia affects 1.62 billion people, which corresponds to 24.8% of the population. The highest prevalence is in preschool-age children and the lowest prevalence is in men. However, the population group with the greatest number of individuals affected is non-pregnant women.
North America is expected to Dominate the Anemia Drug Market.
By region, the global anemia drugs market has been segmented into North America, Europe, Asia Pacific, and the Middle East & Africa. Globally, North America is the largest market for anemia drugs owing to increasing healthcare infrastructure and advanced technology, high research activities and growing awareness about anemia in this region. Asia pacific region is anticipated to show the fastest growth due to increasing health care expenditure and disposable income, high prevalence of chronic diseases and increasing geriatric population.
Key Benefits for Market Reports –
By Anemia Type:
By Regional & Country Level:
Interested in this report?
Anemia Drugs Market Overview & Potential Growth Opportunities 2020-2025